Merck (SNSE:MRK) - Stock Price, News & Analysis

MRK Stock Overview

Operates as a healthcare company worldwide. More details

MRK fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	5/6
Financial Health	4/6
Dividends	4/6

Rewards

Trading at 60.3% below our estimate of its fair value

Earnings are forecast to grow 15.5% per year

Earnings grew by 163.6% over the past year

Analysts in good agreement that stock price will rise by 33.9%

Risk Analysis

Large one-off items impacting financial results

Has a high level of debt

Merck & Co., Inc. Competitors

Roche Holding

SWX:ROG

CHF 210.3b

AstraZeneca

LSE:AZN

UK£159.6b

Novartis

SWX:NOVN

CHF 185.4b

Johnson & Johnson

NYSE:JNJ

US$368.9b

Price History & Performance

Summary of all time highs, changes and price drops for Merck
Historical stock prices
Current Share Price	US$128.80
52 Week High	US$128.80
52 Week Low	US$111.28
Beta	0.41
11 Month Change	0%
3 Month Change	0%
1 Year Change	24.16%
33 Year Change	59.31%
5 Year Change	53.92%
Change since IPO	176.22%

Recent updates

Shareholder Returns

	MRK	CL Pharmaceuticals	CL Market
7D	0%	0%	0%
1Y	24.2%	0%	0%

Return vs Industry: MRK exceeded the CL Pharmaceuticals industry which returned -17.5% over the past year.

Return vs Market: MRK exceeded the CL Market which returned 10.2% over the past year.

Price Volatility

Is MRK's price volatile compared to industry and market?
MRK volatility
MRK Average Weekly Movement	0%
Pharmaceuticals Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in CL Market	0%
10% least volatile stocks in CL Market	0%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine MRK's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1891	71,000	Rob Davis	www.merck.com

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Merck & Co., Inc. Fundamentals Summary

How do Merck's earnings and revenue compare to its market cap?
MRK fundamental statistics
Market cap	US$248.81b
Earnings (TTM)	US$12.15b
Revenue (TTM)	US$63.17b

20.5x

P/E Ratio

3.9x

P/S Ratio

Is MRK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MRK income statement (TTM)
Revenue	US$63.17b
Cost of Revenue	US$14.79b
Gross Profit	US$48.39b
Other Expenses	US$36.24b
Earnings	US$12.15b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 04, 2025

Earnings per share (EPS)	4.80
Gross Margin	76.59%
Net Profit Margin	19.23%
Debt/Equity Ratio	85.6%

How did MRK perform over the long term?

See historical performance and comparison

Dividends

3.1%

Current Dividend Yield

63%

Payout Ratio

MRK Stock Overview

Rewards

Risk Analysis

Merck & Co., Inc. Competitors

SWX:ROG

CHF 210.3b

LSE:AZN

UK£159.6b

SWX:NOVN

CHF 185.4b

NYSE:JNJ

US$368.9b

Price History & Performance

Recent News & Updates

Alexion, AstraZeneca Rare Disease and Merck Announces Positive Topline Results from the Phase 3 Komet Trial

Merck Announces Canada's Drug Agency Recommends WINREVAIR (sotatercept) for Reimbursement

New minor risk - Earnings quality

Third quarter 2024 earnings released: EPS: US$1.24 (vs US$1.87 in 3Q 2023)

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

CDC's ACIP Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older

Recent updates

Alexion, AstraZeneca Rare Disease and Merck Announces Positive Topline Results from the Phase 3 Komet Trial

Merck Announces Canada's Drug Agency Recommends WINREVAIR (sotatercept) for Reimbursement

New minor risk - Earnings quality

Third quarter 2024 earnings released: EPS: US$1.24 (vs US$1.87 in 3Q 2023)

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

CDC's ACIP Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older

Merck's KEYTRUDA® (Pembrolizumab) Receives 30th Approval from European Commission with Two New Indications in Gynecologic Cancers

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Merck Announces the Presentation of Positive Results from the Phase 2B/3 Clinical Trial (Mk-1654-004) Evaluating Clesrovimab

Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease

Merck & Co., Inc. to Report Q3, 2024 Results on Oct 31, 2024

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Merck Announces Overall Survival Results from the Final Analysis of the Phase 3 Keynote-811 Trial Evaluating Keytruda® (Pembrolizumab)

Upcoming dividend of US$0.77 per share

Merck Announces WINREVAIR (Sotatercept) Is Authorized for Use in Canada for Adults with Pulmonary Arterial Hypertension

Merck & Co., Inc. and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™? for the Treatment of Diabetic Macular Edema

European Commission Approves Merck's KEYTRUDA (Pembrolizumab) Plus Padcev (Enfortumab Vedotin-Ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults

Merck & Co., Inc. Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials

Merck Receives European Commission Approval for Winrevair (Sotatercept) in Combination with Other Pulmonary Arterial Hypertension (Pah) Therapies, for the Treatment of Pah in Adult Patients with Functional Class II-III

Health Canada Approves Merck's KEYTRUDA® for the Treatment of Adult Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer with No Prior Systemic Therapy for mUC, in Combination with Enfortumab Vedotin

Merck & Co., Inc. Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer

Daiichi Sankyo and Merck Announces IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

Merck & Co., Inc. Revises Earnings Guidance for the Year 2024

Insufficient new directors

Second quarter 2024 earnings released: EPS: US$2.14 (vs US$2.35 loss in 2Q 2023)

First quarter dividend of US$0.77 announced

Merck Receives Positive Eu Chmp Opinion for Keytruda® (Pembrolizumab) PPlus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma